• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于治疗炎症性肠病的小分子治疗药物。

Small therapeutic molecules for the treatment of inflammatory bowel disease.

作者信息

van Deventer S J H

机构信息

Department of Hepato-Gastroenterology, Academic Medical Center, Amsterdam, the Netherlands.

出版信息

Gut. 2002 May;50 Suppl 3(Suppl 3):III47-53. doi: 10.1136/gut.50.suppl_3.iii47.

DOI:10.1136/gut.50.suppl_3.iii47
PMID:11953333
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1867685/
Abstract

New therapies for inflammatory bowel disease are needed, because standard therapies fail to induce remission in about 30% of patients, and because of the relative inefficacy of current maintenance therapies. This review summarises the current status of the development of small therapeutic molecules for inflammatory bowel disease.

摘要

炎症性肠病需要新的治疗方法，因为标准疗法在约30%的患者中无法诱导缓解，且当前维持疗法的相对疗效不佳。本综述总结了用于炎症性肠病的小分子治疗药物的研发现状。

相似文献

1
Small therapeutic molecules for the treatment of inflammatory bowel disease.用于治疗炎症性肠病的小分子治疗药物。
Gut. 2002 May;50 Suppl 3(Suppl 3):III47-53. doi: 10.1136/gut.50.suppl_3.iii47.
2
BMS-561392. Bristol-Myers Squibb.BMS - 561392。百时美施贵宝公司。
Curr Opin Investig Drugs. 2003 May;4(5):598-602.
3
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor therapies. Foreword.英夫利昔单抗及其他抗肿瘤坏死因子疗法治疗炎症性肠病。前言。
BioDrugs. 2010 Dec 14;24 Suppl 1:1-2. doi: 10.2165/11586300-000000000-00000.
4
Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.未来的新型药物：炎症性肠病中抗TNF药物之外的治疗方法
J Dig Dis. 2014 Nov;15(11):585-90. doi: 10.1111/1751-2980.12193.
5
Next generation of small molecules in inflammatory bowel disease.炎症性肠病中的新一代小分子药物。
Gut. 2017 Feb;66(2):199-209. doi: 10.1136/gutjnl-2016-312912. Epub 2016 Nov 17.
6
Thalidomide in inflammatory bowel disease: too little, too soon.沙利度胺用于炎症性肠病：用量过少，为时过早。
J Gastroenterol Hepatol. 2002 Mar;17(3):233-5. doi: 10.1046/j.1440-1746.2002.02706.x.
7
Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results.沙利度胺治疗儿童及青年难治性炎症性肠病的疗效和安全性：长期结果
Aliment Pharmacol Ther. 2007 Feb 15;25(4):419-27. doi: 10.1111/j.1365-2036.2006.03211.x.
8
Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.基于色满的肿瘤坏死因子-α转换酶（TACE）抑制剂：设计、合成及生物学评价。
Bioorg Med Chem. 2008 Jan 1;16(1):530-5. doi: 10.1016/j.bmc.2007.09.014. Epub 2007 Sep 14.
9
Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.药物洞察：肿瘤坏死因子-α拮抗剂在炎症性肠病治疗中的应用
Nat Clin Pract Gastroenterol Hepatol. 2006 Apr;3(4):220-8. doi: 10.1038/ncpgasthep0447.
10
[Mexican consensus on the use of agents anti-TNF-alpha in the treatment of inflammatory bowel disease.].[墨西哥关于使用抗TNF-α药物治疗炎症性肠病的共识。]
Rev Gastroenterol Mex. 2009;74(3):263-78.

引用本文的文献

1
The Non-Peptide MAS-R Agonist AVE0991 Alleviates Colitis Severity in Mice and Exhibits an Additive Effect with Azathioprine.非肽类MAS-R激动剂AVE0991减轻小鼠结肠炎严重程度并与硫唑嘌呤呈现相加效应。
Int J Mol Sci. 2025 Jun 17;26(12):5784. doi: 10.3390/ijms26125784.
2
Minocycline synergizes with corticosteroids in reducing colitis severity in mice via the modulation of pro-inflammatory molecules.米诺环素与皮质类固醇协同作用，通过调节促炎分子减轻小鼠结肠炎的严重程度。
Front Pharmacol. 2023 Nov 16;14:1252174. doi: 10.3389/fphar.2023.1252174. eCollection 2023.
3
Osthole pretreatment alleviates TNBS-induced colitis in mice via both cAMP/PKA-dependent and independent pathways.蛇床子素预处理通过cAMP/PKA依赖性和非依赖性途径减轻三硝基苯磺酸诱导的小鼠结肠炎。
Acta Pharmacol Sin. 2017 Aug;38(8):1120-1128. doi: 10.1038/aps.2017.71. Epub 2017 Jun 12.
4
Solid-phase parallel synthesis of drug-like artificial 2H-benzopyran libraries.药物样人工 2H-苯并吡喃库的固相平行合成。
Molecules. 2012 May 9;17(5):5467-96. doi: 10.3390/molecules17055467.
5
Thalidomide induces mucosal healing in Crohn's disease: case report.沙利度胺诱导克罗恩病黏膜愈合：病例报告。
World J Gastroenterol. 2011 Dec 7;17(45):5028-31. doi: 10.3748/wjg.v17.i45.5028.
6
Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution.雷贝拉唑通过增强上皮修复促进结肠溃疡愈合。
World J Gastroenterol. 2011 Sep 7;17(33):3802-9. doi: 10.3748/wjg.v17.i33.3802.
7
Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells.人结肠上皮细胞中的肿瘤坏死因子-α转化酶（TACE）活性
Clin Exp Immunol. 2004 Jan;135(1):146-53. doi: 10.1111/j.1365-2249.2004.02348.x.
8
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.BRAF基因的突变存在于胆管癌中，而不存在于肝细胞癌中。
Gut. 2003 May;52(5):706-12. doi: 10.1136/gut.52.5.706.

本文引用的文献

1
Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B.沙利度胺和地塞米松对转录因子NF-κB的不同作用
Int Immunopharmacol. 2001 Jan;1(1):49-61. doi: 10.1016/s0162-3109(00)00265-4.
2
Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle.过氧化物酶体增殖物激活受体 (PPAR)γ 和视黄酸 X 受体 (RXR) 激动剂对人体骨骼肌的葡萄糖和脂质代谢具有互补作用。
Diabetologia. 2001 Apr;44(4):444-52. doi: 10.1007/s001250051642.
3
Ridogrel enemas in distal ulcerative colitis.利托格雷灌肠剂治疗远端溃疡性结肠炎
Eur J Gastroenterol Hepatol. 2001 Apr;13(4):397-400. doi: 10.1097/00042737-200104000-00016.
4
Rosiglitazone.罗格列酮
Expert Opin Pharmacother. 2001 Mar;2(3):467-78. doi: 10.1517/14656566.2.3.467.
5
Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans.过氧化物酶体增殖物激活受体γ（PPARγ）的激活及其在人类中的后果。
Toxicol Lett. 2001 Mar 31;120(1-3):9-19. doi: 10.1016/s0378-4274(01)00302-2.
6
Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.沙利度胺长期治疗儿童及年轻成人克罗恩病的疗效：初步结果
J Pediatr Gastroenterol Nutr. 2001 Feb;32(2):178-81. doi: 10.1097/00005176-200102000-00016.
7
The physiological expression of inducible nitric oxide synthase (iNOS) in the human colon.诱导型一氧化氮合酶（iNOS）在人结肠中的生理表达。
J Clin Pathol. 2001 Apr;54(4):293-7. doi: 10.1136/jcp.54.4.293.
8
Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies.通过视黄酸X受体（RXR）/过氧化物酶体增殖物激活受体γ（PPARγ）异二聚体激活剂减轻结肠炎症。新治疗策略的基础。
J Exp Med. 2001 Apr 2;193(7):827-38. doi: 10.1084/jem.193.7.827.
9
Inducible nitric oxide synthase attenuates chronic colitis in human histocompatibility antigen HLA-B27/human beta2 microglobulin transgenic rats.诱导型一氧化氮合酶减轻人类组织相容性抗原HLA - B27/人类β2微球蛋白转基因大鼠的慢性结肠炎。
Eur Cytokine Netw. 2001 Mar;12(1):111-8.
10
Inhibition of nitric oxide synthesis by aminoguanidine increases intestinal damage in the acute phase of rat TNB-colitis.氨基胍对一氧化氮合成的抑制作用会加重大鼠三硝基苯磺酸结肠炎急性期的肠道损伤。
Eur J Clin Invest. 2001 Mar;31(3):234-9. doi: 10.1046/j.1365-2362.2001.00802.x.